[Disclaimer: This article is for educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before beginning any research compound protocol.]
SLU-PP-332 is one of the most talked-about research compounds in the optimization space for the past two years, and for several good reasons.
It activates three estrogen-related receptors (ERRα, ERRβ, ERRγ) simultaneously, activating mechanisms that mimic the cellular signaling cascade triggered by intense aerobic exercise.
Leading to desirable health benefits such as mitochondrial biogenesis, fat oxidation, and endurance adaptation.
But then you have the SLU-PP-332 oral bioavailability problem.
More exactly, there’s been an awful lot of speculation mixed in with dis-information and bro-science when it comes to dosing this compound properly.
I have personally run 400-800mg of SLU-PP-332 daily for multiple cycles, and I have previously covered the high-dose breakthrough and side effect profile of SLU-PP-332 in great detail.
What I AM going to specifically talk about here is what the science and real-world experience tell us about the oral bioavailability of this compound.
And how it can be applied toward using SLU-PP-332 intelligently.
Quick Takeaways
- SLU-PP-332 is orally active based on real-world n-of-1 experimentation at high doses, but formal human pharmacokinetic data does not yet exist
- The animal studies used intraperitoneal (IP) injection, NOT oral administration — a critical distinction most people miss when interpreting the dosing literature
- First-pass hepatic metabolism is the central challenge determining how much of this compound actually reaches systemic circulation
- Allometric scaling from rodent IP injection data yields a human equivalent dose in the hundreds of milligrams range, not the microgram range most early adopters were using
- No need to time the dose of SLU-PP-332 around fat-containing meals, as real-world experience at high doses confirms oral activity without fat co-administration
What Is SLU-PP-332 and How Does It Work?
Understanding bioavailability starts with understanding how the molecule itself works.
SLU-PP-332 is a small-molecule pan-ERR agonist, meaning it binds and activates all three members of the estrogen-related receptor family.
These receptors are nuclear transcription factors responsible for directly regulating genes involved in processes such as oxidative phosphorylation, fatty acid oxidation, and mitochondrial biogenesis.
They do this primarily by recruiting PGC-1α, the master regulator of mitochondrial function.
When you exercise with sufficient intensity, PGC-1α gets activated and your mitochondrial density increases over time.
SLU-PP-332 works by hitting the same downstream target, except through a receptor-mediated shortcut.
For context on how SLU-PP-332 fits alongside other exercise mimetics and mitochondrial compounds, MOTS-c and SS-31 approach the same mitochondrial optimization problem through entirely different pathways and stack intelligently with this compound.
Why SLU-PP-332 Oral Bioavailability Is the Key Variable
Most people assume when a compound is administered in a study, the delivery route will directly translate to how they intend to use it for themselves.
That assumption, specifically for SLU-PP-332, is incorrect to the point where it misled the entire health optimization community for nearly a year before someone put 2 and 2 together.
The landmark animal studies demonstrating enhanced endurance, fat loss, and cardiac function used intraperitoneal (IP) injection.
They did NOT use oral administration!
IP injections deliver the compound directly into the body cavity for rapid organ-level exposure.
Which is far and away from being the same thing as swallowing a capsule.
Cyrielle Billon’s 2024 paper on ERR agonism and metabolic syndrome — one of the foundational studies behind the current dosing conversation — used mice injected IP with 50 mg/kg SLU-PP-332 twice daily.
This distinction matters enormously when you try to extrapolate human oral dosing from that data.
Oral bioavailability is determined by multiple sequential barriers:
- Gastrointestinal stability
- Intestinal absorption efficiency
- First-pass hepatic metabolism
- Plasma protein binding
SLU-PP-332 is a lipophilic small molecule, which means reasonable gastrointestinal stability and passive diffusion across intestinal membranes are plausibly expected.
However, lipophilic compounds are also prime substrates for cytochrome P450 enzymes (particularly CYP3A4) that live in both the gut wall and the liver.
This is where significant first-pass extraction can occur, reducing effective systemic exposure far below the administered dose of the compound in question.
My current working estimate is SLU-PP-332’s oral bioavailability is somewhere below 50% — and if it were at the extremely low end of 2% to 5%, the doses required would be in the multiple gram range to achieve meaningful therapeutic exposure.
The fact that real-world results are being seen at 400 to 800mg oral suggests bioavailability is meaningfully higher than the worst-case scenario, but formal pharmacokinetic data to confirm this observation does not yet exist.
SLU-PP-332 Dosing and the Allometric Scaling Problem
Here is where most people went wrong, and I AM including supposedly knowledgeable sources in this space within my definition of “most people.”
Allometric scaling is the science of adjusting doses across species based on differences in body surface area, metabolic rate, and organ function.
Taking Cyrielle Billon’s paper as the reference: Mice were dosed at 50 mg/kg IP twice daily, leading to a daily total of 100 mg/kg.
Dividing by the standard mouse-to-human conversion factor of 12.3 gives a human-equivalent dose of approximately 8.13 mg/kg.
For an 80kg individual, this comes out to roughly 650mg per day.
That is easily a +100-fold difference from the microgram doses most early adopters were using, which explains why early protocols produced underwhelming results.
While this is a big step forward, we are far away from the final answer.
As I just mentioned earlier in this article, we are still lacking comprehensive pharmacokinetic data pertaining to half-life, peak plasma concentration, and confirmed bioavailability in humans.
So far now, the best we can do is combine physiological logic with real-world n-of-1 experimentation actually shows.
Does Oral SLU-PP-332 Work? Real-World High-Dose Results
I ran 400-800mg of oral SLU-PP-332 daily for three weeks, split into morning and afternoon doses.
The results were unmistakable:
- Improved sleep
- Increased strength and torque generation
- Better vascularity
- Greater muscular density and leanness
- Higher cellular energy levels
- The ability to train harder for longer without fatigue
The fact these results occurred within the 400-800mg dosage range is itself an early sign meaningful pharmacokinetic data.
At the bare minimum, we can confirm a sufficient amount of SLU-PP-332 is reaching systemic circulation to produce the expected receptor-level effects.
The oral route works, but the next critical variable to finalize is the optimal therapeutic dose (and what a potentially dangerous dose could look like).
There is one important finding I want to share that contradicts some of the theoretical guidance about lipophilic compounds: It is not necessary to time SLU-PP-332 around fatty meals for better absorption.
Real-world experience at high doses confirms effective oral activity regardless of meal composition, so just take it and get on with your day.
For the full breakdown of what the high-dose protocol looks like and what to expect, my high-dose SLU-PP-332 article covers the complete picture.
SLU-PP-332 Oral Bioavailability: Myth vs Reality
| Myth | Reality |
| “The animal studies confirm oral bioavailability” | The landmark studies used IP injection, not oral administration |
| “Microdosing at 500mcg is evidence-based” | Early dosing was 100x too low based on allometric scaling from the actual study data |
| “It works the same in humans as in mice at the same mg/kg dose” | Allometric scaling and metabolic differences make direct dose translation invalid |
| “You must take it with fat for absorption” | Real-world high-dose oral use confirms activity without fat co-administration |
| “More is always better” | Receptor saturation and off-target considerations still apply — escalate intelligently |
SLU-PP-332 Safety, Risks, and Contraindications
DO NOT approach this compound casually.
Preclinical safety data from 28-day continuous use in mice shows no liver, kidney, or cardiac toxicity and no severe adverse effects at the doses studied.
That is reassuring as a baseline signal, but human safety data is what we all want at the end of the day.
Key risk considerations include some of hte following:
- Cardiac effects: ERR agonism influences cardiac metabolism.
- Animal data shows protective effects in heart failure models, but individual cardiac responses cannot be predicted without clinical data.
- Hormonal interactions: Despite the name, estrogen-related receptors are not estrogen receptors and SLU-PP-332 does not directly modulate estrogen.
- However, ERR and estrogen receptor signaling pathways share coactivators and “cross-talk” exists.
- Anyone with hormone-sensitive conditions should be aware of this mechanistic overlap.
- ROS and free radical formation: When you drive mitochondria to operate at higher efficiency, there is potential for increased reactive oxygen species production.
- This is why post-cycle mitochondrial support and antioxidant protocols matter.
- I use pomegranate, Urolithin A, Vitamin C, Carbon 60, and SS-31 specifically during my off-cycles to manage this.
- Unknown long-term effects: No chronic human exposure data exists.
- Cycle it — 8 weeks on, 8 weeks off.
Finally, DO NOT source this compound from gray-market vendors who cannot verify the identity, purity, and concentration of the SLU-PP-332 they provide.
BioLongevity Supplements’ ShredMAX, dosed at 100mg per capsule, is the product I use and recommend.
Use code JAY15 for 15% OFF!
For a comprehensive breakdown of the full risk and side effect profile based on all available preclinical data, see my dedicated SLU-PP-332 side effects article.
How to Use SLU-PP-332 the Right Way
SLU-PP-332 is objectively an interesting compound, but you must approach it with accurate information about what the science actually says in regard to its safety and efficacy.
Most people in this space made two critical errors:
- They assumed the animal data came from oral administration when it came from IP injection (or simply didn’t care and thought IP would directly translate to oral)
- They used doses 100x too low as a result of #1.
Solving the bioavailability question starts with understanding the thinking that led to these two errors.
Once you fix this error, as myself and many people now have, you’ll find the real-world high-dose oral use at the allometrically scaled range produces results that match the compound’s biological promises.
From there, you can support your mitochondria with foundational mitochondrial compounds both during and after your SLU-PP-332 cycles.
And this goes without saying: Stop immediately if any adverse signals emerge!
Your Biology Is Your Responsibility
No compound, protocol, or physician removes your personal responsibility for understanding what you are putting in your body.
The current healthcare system will not teach you about SLU-PP-332, ERR biology, mitochondrial optimization, or how to think critically about preclinical-to-human translation.
SLU-PP-332 oral bioavailability is a legitimate scientific question with real implications for anyone using this compound.
The current honest and accurate answer can be summed up in a single sentence:
Formally uncharacterized in humans, but real-world high-dose experience confirms meaningful oral activity at allometrically scaled doses, without fat co-administration requirements.
Anything more confident than that is someone selling you certainty they do not have or telling you something they don’t know about.
Anything less confident ignores the n-of-1 evidence that is accumulating in the optimization community right now.
Get on my list and stay inside the optimization conversation.
This space is moving faster than you can blink!
Isn’t It Time You Became Fully Optimized To Live Leaner, Longer And Stronger?
Join my #1 online membership group, Fully Optimized Health to receive guidance from me and an elite group of more than 700 male and female biohackers (who all started out just like you)
And don’t forget to check out our other premium educational content dedicated to helping you fully optimize your health:
Quantum Peptides – the A-to-Z system for anyone (newbies & pros alike) desiring to master peptide use for the first time and forever.
Quantum Testosterone – the A-to-Z system for Men & Women to learn to optimize their hormones for explosive energy, lean muscle, and timeless vitality.
The Ultimate GLP-1 Video Masterclass – how to PROPERLY utilize the world’s most powerful weight loss drugs for enhanced fat loss and overall longevity.
The Modern Woman’s Peptide Course – a must-have resource for any woman seeking to become more feminine, sexier, leaner, and healthier through the use of peptides.
Life Enhanced – Unlock the secrets to TOTAL Mind-Body-Spirit Optimization as Hunter Williams and I teach you how to live at the tip of the spear.
30 Days 2 Shredz – Reprogram Your Mind and Body for Maximum Fat Loss in Minimum Time with our Optimized Fasting Protocol
Monica Campbell’s 3 Day PMF Video Training Program – Ignite unbreakable strength, sculpt lean muscle, and conquer workouts fearlessly with my wife Monica’s 3 Day Video training course.
Positive Muscle Failure Video Training Program – Learn how to lift weights correctly for maximum muscle in minimum time while building the physique of your dreams.
See you on the inside!
